The University of Michigan Rogel Cancer Center researchers received one of the Prostate Cancer Foundation’s four inaugural Class of 2022 TACTICAL (Therapy ACceleration To Intercept Cancer Lethality) Award. This $30 million program will support cross-disciplinary pioneering research toward the goal of developing 21st Century therapies for the most life-threatening form of prostate cancer [...]
Members of the University of Michigan Department of Pathology and Michigan Center for Translational Pathology, in collaboration with the Clinical Proteomic Tumor Analysis Consortium, recently published a large study on clear cell renal cell carcinomas (ccRCCs), which represent about 75% of the RCC cases and account for the most RCC-associated deaths. This study set out to create a comprehensive profile of ccRCC, combining histologic and molecular profiles. By analyzing both the microscopic cell structures and the genetic makeup of the cells, these researchers discovered significant intratumoral heterogeneity in 90% of ccRCCs. This indicates that ccRCCs originate from multiple tumor cell lines, called tumor subclones, that may become metastatic and could independently influence response to therapies. Through this study, the team was able to molecularly stratify aggressive histopathic subtypes, which may lead to more effective treatment strategies for patients and improved survival.
The Celina Kleer lab at the University of Michigan Department of Pathology and Rogel Cancer Center has found a new mechanism that fuels metastasis in triple negative breast cancers. In their new study they show that EZH2, a master regulator of cell type identity, known to function through methylation of histones, has a new, unexpected function in aggressive breast cancers [...]
Patients with relapsed multiple myeloma are resistant to commonly used treatments. Researchers are one step closer to understanding the genetic reason why.
Dr. Xiao-Ming (Mindy) Wang and colleagues from the Michigan Center for Translational Pathology and Department of Pathology published a groundbreaking finding from an inter-institutional study regarding TRIM63 in Modern Pathology [...]
Findings offer clues to why some types of renal cell carcinoma respond to immunotherapy while others do not — it’s a scientific riddle tangled up in a complex web. How do you turn an immune cold cancer into one that responds to immunotherapy?
Not all kidney cancers behave the same, with wildly different responses to immunotherapy or other treatments – and wildly different outcomes for patients as a result. By sequencing the RNA of individual cells within multiple benign and cancerous kidney tumors, researchers from the University of Michigan Rogel Cancer Center have identified the cells [...]
A research effort by Drs. Jolanta Grembecka and Tomasz Cierpicki was just published in Nature Communications. Learn more about the protein made by the ASH1L gene, which plays a key role in the development of acute leukemia, along with other diseases [...]
MiTF renal cell carcinoma can masquerade as other subtypes and may not respond as well to front-line therapies.
A new study by the University of Michigan's Rogel Cancer Center analyzed patients with cancer and the factors that cause the cancer to spread to the liver, leading to worse outcomes.
Clinical trials underway are testing whether drugs that target the androgen receptor – successful in controlling prostate cancer – could also work against the coronavirus. wo proteins, ACE2 and TMPRSS2, help the coronavirus gain entry and replicate within cells. TMPRSS2 is well-known to Arul Chinnaiyan, MD, PhD. His lab discovered that TMPRSS2 fuses with the ETS gene to drive more than half of all prostate cancers [...]
A new study led by Drs. Jolanta Grembecka and Tomasz Cierpicki of the Department of Pathology was just published in Blood's American Society of Hematology. The research focuses on combinatorial treatment with menin and FLT3 and how inhibitors induce complete remission in acute myeloid leukemia (AML) with activating FLT3 mutations [...]
Congratulations to Dr. Celina Kleer who was awarded the American Society for Investigative Pathology (ASIP)'s 2020 Outstanding Investigator Award. Dr. Kleer receives the award for her demonstrated excellence in research in experimental pathology [...]
Structural biology techniques helped researchers target the nuclear receptor-binding SET domain family, whose malfunction is associated with several types of cancer.
Dr. Celina Kleer named 2019 AACR Outstanding Investigator in Breast Cancer Research
A Phase I clinical trial, using a structurally related analog of the compound, is currently enrolling patients.
The American Association for Cancer Research announced that Celina Kleer, MD, the Harold A. Oberman Collegiate Professor of Pathology and Director of the Breast Pathology Program, will be the recipient of the 2019 Outstanding Investigator in Breast Cancer Research, supported by the Breast Cancer Research Foundation.